Sana Biotechnology (SANA) H.C. Wainwright 27th Annual Global Investment Conference summary

Business overview and technology platforms

• Focus on two foundational platforms: Hypoimmune for immune evasion and Fusogen for cell-specific in vivo delivery.

• Hypoimmune Platform aims to overcome allogeneic rejection by gene editing to disrupt MHC I/II and overexpress CD47, enabling true immune evasion.

• Fusogen Platform enables targeted delivery of genetic material to specific cells, supporting in vivo CAR T therapies.

Type 1 diabetes program and clinical data

• Proof-of-concept study in type 1 diabetes showed successful transplantation of Hypoimmune-modified islets without immunosuppression.

• Patient produced insulin for the first time in over 30 years, with stable C-peptide and no safety events over six months.

• Imaging confirmed survival of transplanted islets at the injection site.

• Immune evasion demonstrated: modified islets were not attacked by T cells, antibodies, or natural killer cells.

• IND filing for SC451 expected as early as next year.

Allogeneic CAR T and in vivo CAR T programs

• SC291 (CD19-directed) and SC262 (CD22-directed) allogeneic CAR T programs are in phase I trials for autoimmune diseases and blood cancers.

• SC291 showed deep, dose-dependent B cell depletion in oncology; GLEAM and VIVID trials are ongoing with data expected in 2025.

• SG299, an in vivo CD19-directed CAR T, demonstrated deep B-cell depletion in non-human primates without lymphodepletion; IND filing expected by 2026.